Selumetinib

Active substance

Selumetinib

Holder

AstraZeneca AB

Status

Running

Indication

neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1 (NF1) aged ≥ 3 years and ≤ 18 years.

Public documents 

Approbation

Information for the patient

Informed consent

Last update

11/08/2022

Last updated on 27/11/2023